Abstract

Background and Aim: The incidences of sepsis and septic shock depend on how acute organ dysfunction and infection are defined as well as on which data sources are studied. Hence this study was conducted to bring out the correlation between hyperuricemia in clinically diagnosed sepsis patients and morbidity and mortality.

Material and Methods: Total of 150 patients was included in the study. For the uric acid estimation of the included patients; blood samples were taken from the patient. For the biochemical estimation of the uric acid level the collaboration was done with the department of biochemistry, medical college and hospital.

Results: Among the 150 study participants, 64 patients had elevated uric acid levels which constitutes about 42.7%, whereas 86 patients constituting 57.3% had normal uric acid levels. It can be inferred that among the study population, patients had type 2 diabetes mellitus as the most common comorbidity at 40%. The most prevalent comorbidities among the patients with hyperuricemia were diabetesmellitus type 2 and type 1, decompensated liver disease and cerebrovascular accident. Patients without any comorbidities about 36% of the study population also developed sepsis.

Conclusion: This study demonstrates that Serum Uric acid may be potentially used as a marker of severity of illness as well as predictor of mortality and morbidity in patients with clinically diagnosed sepsis in the IMCU. This study recommends further studies on a large basis to confirm the observations.

• 1.   Martin CM, Priestap F, Fisher H, Fowler RA, Heyland DK, Keenan SP, et al. A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry. Crit Care Med. 2009;37(1):81-8.
• 2.   Jolley RJ, Sawka KJ, Yergens DW, Quan H, Jetté N, Doig CJ. Validity of administrative data in recording sepsis: a systematic review. Crit Care. 2015;19(1):1-12.
• 3.   Rhee C, Jentzsch MS, Kadri SS, Seymour CW, Angus DC, Murphy DJ, et al. Variation in identifying sepsis and organ dysfunction using administrative versus electronic clinical data and impact on hospital outcome comparisons. Crit Care Med. 2019;47(3):493-500.
• 4.   Ronco C, Bonello M, Bordoni V, Ricci Z, D’Intini V, Bellomo R, et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif. 2004;22(2):164-74.
• 5.   Rubio PEA, Molina RB, Ávila PEA, Mora AG, López CAG. Infective Endocarditis: Inflammatory Response, Genetic Susceptibility, Oxidative Stress, and Multiple Organ Failure. In: Infective Endocarditis. London: IntechOpen; 2019.
• 6.   Barrett KE, Boitano S, Barman SM, Brooks HL. Ganong’s review of medical physiology. 23rd ed. New York: McGraw Hill Professional; 2010.
• 7.   Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders–facts and controversies. Biochem Med. 2012;22(1):63-75.
• 8.   Akbar SR, Long DM, Hussain K, Alhajhusain A, Ahmed US, Iqbal HI, et al. Hyperuricemia: an early marker for severity of illness in sepsis. Int J Nephrol. 2015;2015:240759.
• 9.   Victor VM, Rocha M, Esplugues JV. Role of free radicals in sepsis: antioxidant therapy. Crit Care Drug. 2005;11(11):3141-58.
• 10.   El-Shebiny E, Daif S, Shoeib S, Fathi Y, Zahran E. Serum uric acid level as a prognostic factor in sepsis outcome. Egypt J Chest Dis Tuberc. 2022;71(1):20.
• 11.   Lappas M, Hiden U, Desoye G, Froehlich J, Mouzon SH, Jawerbaum A. The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. Arch Gynecol Obstet. 2011;15(12):3061-100.
• 12.   Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol. 2011;22(6):999-1006.
• 13.   Bhargavi Sindhuja N. A Study on Hyperuricemia as an Early Marker for Severity of Illness in Sepsis in IMCU of a Tertiary Care Centre [dissertation]. Vellore: Government Vellore Medical College; 2020.
• 14.   Kocyigit I, Yilmaz MI, Orscelik O, Sipahioglu MH, Unal A, Eroglu E, et al. Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2013;123(2):157-64.

Data Sharing Statement

Funding